TISSIUM’s De Novo FDA Authorization Signals Industry Shift
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Read MorePosted by Shajini | Jun 25, 2025 | Device Approvals, MedTech, Neurology, News |
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Read MorePosted by Shajini | Jun 25, 2025 | Dealstreet, News
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
Read MorePosted by Shajini | Jun 23, 2025 | News, Regulatory
ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
Read MorePosted by Shajini | Jun 22, 2025 | Neurology, News, Pricing & Market Access
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
Read MorePosted by Shajini | Jun 10, 2025 | News, Oncology, Regulatory
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
Read More